Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups

References

• (UNODC) UNOoDaC. World drug report 2018. United Nations publication, Sales No. E.18.XI.9; 2018.
   Google Scholar
• Addiction EMCfDaD. European drug report 2019: trends and developments. Brussels, Belgium: European Monitoring Center for Drugs and Drug Additcion (EMCDDA); 2019.
   Google Scholar
• Rawson RA, Marinelli-Casey P, Anglin MD, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004 Jun;99(6):708–717.
   PubMed Web of Science ®Google Scholar
• Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681–698.
   PubMed Web of Science ®Google Scholar
• Gough B, Pereira FC, Fontes Ribeiro CA, et al. Propentophylline increases striatal dopamine release but dampens methamphetamine-induced dopamine dynamics: A microdialysis study. Neurochem Int. 2014;76:109–113.
   PubMed Web of Science ®Google Scholar
• Pereira FC, Gough B, Macedo TR, et al. Buprenorphine modulates methamphetamine-induced dopamine dynamics in the rat caudate nucleus. Neurotox Res. 2011 Jan;19(1):94–101.
   PubMed Web of Science ®Google Scholar
• Pereira FC, Lourenco E, Milhazes N, et al. Methamphetamine, morphine, and their combination: acute changes in striatal dopaminergic transmission evaluated by microdialysis in awake rats. Ann N Y Acad Sci. 2006;1074:160–173.
   PubMed Web of Science ®Google Scholar
• Pereira FC, Macedo TR, Imam SZ, et al. Lack of hydroxyl radical generation upon central administration of methamphetamine in rat caudate nucleus: a microdialysis study. Neurotox Res. 2004;6(2):149–152.
   PubMed Web of Science ®Google Scholar
• Pereira FC, Imam SZ, Gough B, et al. Acute changes in dopamine release and turnover in rat caudate nucleus following a single dose of methamphetamine. J Neural Transm. 2002 Sep;109(9):1151–1158.
   PubMed Web of Science ®Google Scholar
• Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013 May 1;129(3):167–179.
   PubMed Web of Science ®Google Scholar
• Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009 Jul;104(7):1085–1099.
   PubMed Web of Science ®Google Scholar
• Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006 Mar 3;6:6.
   PubMedGoogle Scholar
• Moszczynska A, Callan SP. Molecular, behavioral, and physiological consequences of methamphetamine neurotoxicity: implications for treatment. J Pharmacol Exp Ther. 2017 Sep;362(3):474–488.
   PubMed Web of Science ®Google Scholar
• Darke S, Kaye S, McKetin R, et al. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008 May;27(3):253–262.
   PubMed Web of Science ®Google Scholar
• Yang X, Wang Y, Li Q, et al. The main molecular mechanisms underlying methamphetamine- induced neurotoxicity and implications for pharmacological treatment. Front Mol Neurosci. 2018;11:186.
   PubMed Web of Science ®Google Scholar
• Tait RJ, Whetton S, Shanahan M, et al. Quantifying the societal cost of methamphetamine use to Australia. Int J Drug Policy. 2018;62:30–36.
   PubMed Web of Science ®Google Scholar
• Turton S. Neurobiology and principles of addiction and tolerance. Medicine (Baltimore). 2016;44(12):693–696.
   Google Scholar
• Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol. 2005 Feb;5(1):9–19.
   PubMed Web of Science ®Google Scholar
• Ballester J, Valentine G, Sofuoglu M. Pharmacological treatments for methamphetamine addiction: current status and future directions. Expert Rev Clin Pharmacol. 2017 Mar;10(3):305–314.
   PubMed Web of Science ®Google Scholar
• Morley KC, Cornish JL, Faingold A, et al. Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opin Investig Drugs. 2017 May;26(5):563–578.
   PubMed Web of Science ®Google Scholar
• Lee NK, Jenner L, Harney A, et al. Pharmacotherapy for amphetamine dependence: A systematic review. Drug Alcohol Depend. 2018 Oct 1;191:309–337.
   PubMed Web of Science ®Google Scholar
• Anderson AL, Li SH, Biswas K, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012 Jan 1;120(1–3):135–141.
   PubMed Web of Science ®Google Scholar
• Anderson AL, Li SH, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015 May 1;150:170–174.
   PubMed Web of Science ®Google Scholar
• Coffin PO, Santos GM, Das M, et al. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Apr;108(4):751–761.
   PubMed Web of Science ®Google Scholar
• Cruickshank CC, Montebello ME, Dyer KR, et al. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev. 2008 May;27(3):326–333.
   PubMed Web of Science ®Google Scholar
• Galloway GP, Buscemi R, Coyle JR, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011 Feb;89(2):276–282.
   PubMed Web of Science ®Google Scholar
• Heinzerling KG, Shoptaw S, Peck JA, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006 Dec 1;85(3):177–184.
   PubMed Web of Science ®Google Scholar
• Heinzerling KG, Swanson AN, Kim S, et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010 Jun 1;109(1–3):20–29.
   PubMed Web of Science ®Google Scholar
• Hester R, Lee N, Pennay A, et al. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence. Exp Clin Psychopharmacol. 2010 Dec;18(6):489–497.
   PubMed Web of Science ®Google Scholar
• Lee N, Pennay A, Hester R, et al. A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes. Drug Alcohol Rev. 2013 Jan;32(1):88–95.
   PubMed Web of Science ®Google Scholar
• Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014 Sep;109(9):1489–1500.
   PubMed Web of Science ®Google Scholar
• Longo M, Wickes W, Smout M, et al. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010 Jan;105(1):146–154.
   PubMed Web of Science ®Google Scholar
• Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Jul;108(7):1279–1286.
   PubMed Web of Science ®Google Scholar
• Morabbi MJ, Razaghi E, Moazen-Zadeh E, et al. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. Int Clin Psychopharmacol. 2018 Mar;33(2):111–119.
   PubMed Web of Science ®Google Scholar
• Rezaei F, Emami M, Zahed S, et al. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. Daru. 2015 Jan 15;23:2.
   PubMed Web of Science ®Google Scholar
• Rezaei F, Ghaderi E, Mardani R, et al. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial. Fundam Clin Pharmacol. 2016 Jun;30(3):282–289.
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008 Aug 1;96(3):222–232.
   PubMed Web of Science ®Google Scholar
• Heinzerling KG, Swanson AN, Hall TM, et al. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction. 2014 Nov;109(11):1878–1886.
   PubMed Web of Science ®Google Scholar
• Brensilver M, Heinzerling KG, Swanson AN, et al. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence. Exp Clin Psychopharmacol. 2012 Oct;20(5):430–435.
   PubMed Web of Science ®Google Scholar
• Brown ES, Gabrielson B. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord. 2012 Dec 20;143(1–3):257–260.
   PubMed Web of Science ®Google Scholar
• Ling W, Shoptaw S, Hillhouse M, et al. Double-blind placebo-controlled evaluation of the PROMETA protocol for methamphetamine dependence. Addiction. 2012 Feb;107(2):361–369.
   PubMed Web of Science ®Google Scholar
• Elkashef A, Kahn R, Yu E, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012 Jul;107(7):1297–1306.
   PubMed Web of Science ®Google Scholar
• Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacol. 2008 Apr;33(5):1162–1170.
   PubMed Web of Science ®Google Scholar
• Hermanstyne KA, Santos GM, Vittinghoff E, et al. Event-level relationship between methamphetamine use significantly associated with non-adherence to pharmacologic trial medications in event-level analyses. Drug Alcohol Depend. 2014 Oct 1;143:277–280.
   PubMed Web of Science ®Google Scholar
• Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011 Nov;68(11):1168–1175.
   PubMed Web of Science ®Google Scholar
• Rawson RA, Gonzales R, Marinelli-Casey P, et al. Methamphetamine dependence: a closer look at treatment response and clinical characteristics associated with route of administration in outpatient treatment. Am J Addict. 2007 Jul-Aug;16(4):291–299.
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Huber A, Peck J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006 Oct 15;85(1):12–18.
   PubMed Web of Science ®Google Scholar
• Zorick T, Sugar CA, Hellemann G, et al. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug Alcohol Depend. 2011 Nov 1;118(2–3):500–503.
   PubMed Web of Science ®Google Scholar
• McCann DJ, Li SH. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther. 2012 May;18(5):414–418.
   PubMed Web of Science ®Google Scholar
• Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009 Feb;104(2):224–233.
   PubMed Web of Science ®Google Scholar
• Ma JZ, Johnson BA, Yu E, et al. Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug Alcohol Depend. 2013 Jun 1;130(1–3):45–51.
   PubMed Web of Science ®Google Scholar
• Briones M, Shoptaw S, Cook R, et al. Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial. Drug Alcohol Depend. 2018 Aug 1;189:30–36.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Elkashef AM, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol. 2008 Feb;11(1):1–14.
   PubMed Web of Science ®Google Scholar
• Dean AC, London ED, Sugar CA, et al. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend. 2009 Nov 1;105(1–2):48–55.
   PubMed Web of Science ®Google Scholar
• Cook R, Quinn B, Heinzerling K, et al. Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence. Addiction. 2017 Jun;112(6):1077–1085.
   PubMed Web of Science ®Google Scholar
• Brensilver M, Heinzerling KG, Swanson AN, et al. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend. 2012 Sep 1;125(1–2):169–172.
   PubMed Web of Science ®Google Scholar
• Heinzerling KG, Gadzhyan J, van Oudheusden H, et al. Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. J Adolesc Health. 2013 Apr;52(4):502–505.
   PubMed Web of Science ®Google Scholar
• Shearer J, Shanahan M, Darke S, et al. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev. 2010 May;29(3):235–242.
   PubMed Web of Science ®Google Scholar
• Heinzerling KG, McCracken JT, Swanson AN, et al. COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. J Clin Psychopharmacol. 2012 Feb;32(1):135–137.
   PubMed Web of Science ®Google Scholar
• Brensilver M, Heinzerling KG, Swanson AN, et al. Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. Drug Alcohol Rev. 2013 Jan;32(1):96–99.
   PubMed Web of Science ®Google Scholar
• Reynolds AR, Strickland JC, Stoops WW, et al. Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine. Drug Alcohol Depend. 2017 Dec 1;181:25–29.
   PubMed Web of Science ®Google Scholar
• Rush CR, Stoops WW, Lile JA, et al. Physiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance. Pharmacol Biochem Behav. 2011 Nov;100(1):40–47.
   PubMed Web of Science ®Google Scholar
• Verrico CD, Haile CN, De La Garza R 2nd, et al. Subjective and cardiovascular effects of intravenous methamphetamine during perindopril maintenance: a randomized, double-blind, placebo-controlled human laboratory study. Int J Neuropsychopharmacol. 2016 Jul;19(7):pyw029.
   PubMed Web of Science ®Google Scholar
• De la Garza R 2nd, Yoon JH. Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1827–1830.
   PubMed Web of Science ®Google Scholar
• Kalechstein AD, Yoon JH, Croft DE, et al. Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. Pharmacol Biochem Behav. 2011 Sep;99(3):423–427.
   PubMed Web of Science ®Google Scholar
• De La Garza R 2nd, Newton TF, Haile CN, et al. Rivastigmine reduces “likely to use methamphetamine” in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):141–146.
   PubMed Web of Science ®Google Scholar
• Worley MJ, Swanson AN, Heinzerling KG, et al. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug Alcohol Depend. 2016 May 1;162:245–250.
   PubMed Web of Science ®Google Scholar
• DeYoung DZ, Heinzerling KG, Swanson AN, et al. Safety of intravenous methamphetamine administration during ibudilast treatment. J Clin Psychopharmacol. 2016 Aug;36(4):347–354.
   PubMed Web of Science ®Google Scholar